Mineralys Therapeutics
MLYS
108 hedge funds and large institutions have $572M invested in Mineralys Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 44 increasing their positions, 17 reducing their positions, and 14 closing their positions.
159% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 17
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
6% more capital invested
Capital invested by funds: $540M → $572M (+$32.2M)
4.16% more ownership
Funds ownership: 89.25% → 93.4% (+4.2%)
2% more funds holding
Funds holding: 106 → 108 (+2)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
88% less call options, than puts
Call options by funds: $1K | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13.1M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$6.79M |
| 3 |
JP Morgan Chase
New York
|
+$6.3M |
| 4 |
SC
Stempoint Capital
New York
|
+$5.23M |
| 5 |
Jennison Associates
New York
|
+$5.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$7.27M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$5.27M |
| 3 |
O
OrbiMed
New York
|
-$5.12M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
-$2.38M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.51M |
MLYS Hedge Fund Activity: Q4 2024 in Review
108 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q4 2024, worth a combined $572M — up 6% from $540M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MLYS positions and 14 closed out — a net gain of 2 holders — while 44 added to existing stakes and 17 trimmed.
The largest buyer was Millennium Management, adding an estimated $13.1M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.27M sold.
- 108 institutional investors held Mineralys Therapeutics (MLYS) as of Q4 2024, up from 106 in Q3 2024.
- Funds reported $572M of Mineralys Therapeutics stock for Q4 2024, up 6% quarter-over-quarter.
- 16 funds opened new Mineralys Therapeutics positions in Q4 2024 and 14 closed out, a net change of +2 holders.
- The largest Mineralys Therapeutics buyer in Q4 2024 was Millennium Management, an estimated $13.1M added.
- The largest Mineralys Therapeutics seller in Q4 2024 was Octagon Capital Advisors, an estimated $7.27M sold.
Based on aggregated 13F filings for Q4 2024.